Halofenate
Product Specifications
UNSPSC Description
Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Assay Protocol
https://www.medchemexpress.com/halofenate.html
Smiles
CC(NCCOC(C(C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2)=O)=O
Molecular Weight
415.79
References & Citations
[1]Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate)
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-14998/Halofenate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-14998/
Clinical Information
No Development Reported
CAS Number
26718-25-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
